November 2023: We removed the off-label warning for anastrozole in recommendations 1.7.22 and 1.7.26 on chemoprevention for women at moderate or high risk of breast cancer, in line with the MHRA licence variation.
March 2017: We updated recommendations in section 1.7 on chemoprevention for women with no personal history of breast cancer. These recommendations are marked as .
June 2013: We updated and included new recommendations on genetic testing thresholds, surveillance and risk reduction and treatment strategies for people without breast cancer who are at increased risk because of a family history of breast, ovarian or a related cancer. We included new recommendations on genetic testing thresholds, subsequent surveillance and risk reduction and treatment strategies for people with a diagnosis of breast cancer and a family history of breast, ovarian or a related cancer. These recommendations are marked as .
July 2006: We updated recommendations in section 1.6 on surveillance and strategies for early detection of breast cancer. These recommendations are marked as .
Minor changes since publication
January 2023: We have added a link to information about the surveillance programme for women at very high risk of developing breast cancer, which is run by the NHSBSP.
June 2022: We removed recommendation 1.1.2 on identifying people with a family history of breast cancer, following a review. For more information see the surveillance report on familial breast cancer.
May 2021: We removed the note about the off-label use of tamoxifen because this is now licensed for preventing breast cancer.
November 2019: A link to patient decision aids was added. Recommendation 1.6.5 was updated to add a cross-reference to recommendation 1.6.18 to clarify the topics that should be discussed with a person before making a mammographic surveillance decision.